a diagnosis of PD and a control group of 40 people (chosen from patients' relatives) for a total of 79 individuals. Patients who could complete the survey forms themselves, or with the help of family, were included in the study.
PD diagnosis was provided by a neurology expert based on the UK Parkinson's Disease Society Brain Bank Criteria. The severity of disease was identified using the Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr scale (H & Y) (8, 9) . The study received local ethics committee permission (number 2014/4). Urological evaluation of individuals in the study, including history, physical examination, and urine and blood tests, was completed in the urology clinic. Urological complaints were determined using the International Prostate Symptom Score (IPSS) and overactive bladder (OAB) questionnaire forms (10) .
The IPSS questionnaire form comprises 7 questions about urological complaints and one question about quality of life. For each question, the patient is given a score between 0 and 5 points and these scores are added to obtain a total score. The total score varies from 0 to 35. According to the total score, urinary complaints are classified as mild (0-7), moderate (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and severe (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Quality of life (QoL) is evaluated by the last question and severity of disruption of QoL is determined according to points from 0 to 5 (no disruption to severe) (11).
Results

Sex difference and age
In the patient group 29 (74.4%) were male and 10 (25.6%) female, while in the control group 27 (67.5%) were male and 13 (32.5%) female. In the patient group, there were no differences identified between the sexes in terms of irritative (P = 0.095) and voiding (P = 0.94) complaints, incontinence (P = 0.45), urgency (P = 0.21), nocturia (P = 0.95), and treatment requirements due to urological complaints (P = 0.75) ( Table 1) .
The comparison of female and male patients in the PD group is shown in Table 2 . The mean age of PD patients was 69.7 ± 7.4 years, and the mean age was 67.9 ± 7.7 years in the control group. In terms of age and sex, there was no statistical difference identified between the PD and control group (P = 0.284 and P = 0.777, respectively). There were higher rates of urologic symptoms, irritative (storage) complaints, voiding complaints, overactive bladder score, (Table 2) .
Comparison of PD and control groups
When total IPSS scores and QoL scores were compared between the groups, they were significantly higher in the PD patient group compared to the control group (P = 0.007 and P=0.014, respectively). When IPSS subscores were examined, the scores for question 2 (feeling of need to urinate within 2 h of urination) (P = 0.03) and question 4 (urgency) (P = 0.08) were observed to be significantly higher in the PD group. In terms of other IPSS questions, there were no differences observed (P > 0.05). In the PD patient group, irritative symptoms (P < 0.001), voiding symptoms (P = 0.005), OAB score (P < 0.001), urgency (P < 0.001), leaking (P = 0.005), and treatment requirements due to urological complaints (P < 0.001) were found to be significantly high compared to the control group.
Duration and severity
The duration of PD varied from 1 year to 15 years, with a mean of 5.36 ± 3.52 years and median of 3 years. No association between the duration of disease and total IPSS score (r = 0.072; P = 0.663), QoL (r = -0.090; P = 0.586), irritative symptoms (r = 0.189; P = 0.250), and voiding symptoms (r = 0.091; P = 0.580) was observed. The UPDRS total scores varied from 8 to 60 with a mean of 25.58 ± 113.58. There was no correlation found between total UPDRS points and total IPSS score (r = 0.101; P = 0.539), QoL (r = 0.078; P = 0.528), and irritative symptoms (r = 0.269; P = 0.098). There was no correlation between total IPSS score (r= 0.008; P = 0.963), QoL (r= -0.194; P = 0.236), and irritative symptoms (r = 0.002; P = 0.990) and UPDRS motor points. There was no correlation found between UPDRS cognitive score and total IPSS score (r = 0.073; P = 0.658) and QoL (r = 0.226; P = 0.167); however there was a correlation found with irritative symptoms (r = 0.447; P = 0.004) ( Table 3) .
Age at onset of disease
The age at onset of PD varied from 44 to 78 years and the mean age at onset of PD was identified as 64.46 ± 8.31 years. There was no correlation found between disease onset age and total IPSS score (r = 0.121; P = 0.464), QoL (r = 0.185; P = 0.260), irritative symptoms (r = 0.130; P = 0.431), and voiding symptoms (r = -0.116; P = 0.923) ( Table 4) .
Disease stage (H & Y stage)
The distribution of PD patients according to stage is as follows: 13 patients (33.3%) in stage 1, 14 (35.9%) in stage 2, 11 (28.2%) in stage 3, and 1 (2.6%) in stage 4. The majority of patients were in the early stages of the disease. There was no correlation found between disease stage and total IPSS score (r = 0.187; P = 0.253), QoL score (r = 0.078; P = 0.637), and irritative symptoms (r = 0.363; P = 0.023).
Discussion
In our study lower urinary system symptoms (LUTS) were identified more frequently in the PD patient group compared to the control group. The IPSS total and QoL scores showing severity of urological complaints were observed to be higher in the PD group. The most common urinary complaints in the PD group were irritative bladder symptoms and these were identified significantly more frequently compared to the control group. There was a positive correlation identified between stage and severity of PD and overactive bladder complaints. IPSS scores are important to see the severity, progression, and effect of treatment for urological complaints. A 3-point reduction in IPSS score shows that treatment is effective (11) . The IPSS is mainly used to evaluate obstructive complaints. In our study it was used in both sexes to determine the effect of obstructive symptoms in neurological disease. In the PD patient group there was no difference identified between the sexes in terms of IPSS total scores (P = 0.605). Expected to increase linked to prostate disease in elderly male patients, voiding (obstructive) complaints were found to be similar in women. A study reported that this may be caused by bradykinetic external sphincter and somatic pelvic muscle dysfunction developing linked to neurological disease (12). Though this questionnaire is not validated for women, we used a single form for both sexes. The definition of OAB includes complaints such as frequent urination, urgency, and/or leaking. To assess OAB an 8-question OAB questionnaire form was used. As OAB complaints may be common symptoms in many diseases, it is necessary to exclude causes such as underlying infection and bladder tumors (13) .
Though the IPSS form is generally used to assess obstructive complaints caused by prostate hypertrophy in men, in PD patients there was no difference in total IPSS scores identified between the sexes. In a study comparing total irritative and obstructive common urinary scores between the sexes in PD by Campos-Sousa et al., they reported no differences between the sexes (14) . Similarly, in our study, there were no differences identified between (14) (15) (16) . The lack of differences identified between women and elderly men, who are expected to have more urological complaints linked to prostate growth, is reported to be due to the contribution of neurological changes occurring in PD to urinary complaints (17, 18) . In our study the effect of PD is clearly visible when compared with the control group (P < 0.001).
As reported in the literature, this suggests a relationship between dopaminergic degeneration and LUTS (19) . It is reported to be difficult to determine the degree of the effect of this damage on urological complaints (1). Myers et al. reported a correlation between disease onset age and irritative complaints in PD patients (20) . This result is supported by urodynamic studies showing irritative complaints completed by Araki et al. (21) . However, there are studies reporting contradictory results, including one by Sammour et al. (22) . That study reported that there was no relationship between voiding dysfunction and disease onset age (P = 0.960). Our results are in accordance with those of Sammour et al., showing no correlation between disease onset age and irritative and voiding complaints (P > 0.05).
In our study we did not find any correlation between age and urological symptoms in the PD group (P > 0.05). These results are in accordance with a study by Gray et al. that reported that urological complaints were related to age; however, age did not affect urological complaints (23) .
In our study there was no correlation identified between disease duration and irritative and voiding symptoms. Our study results comply with the study by Compos-Sousa et al., who reported no relationship between disease duration and urinary symptoms (14) . As reported by Diamond et al. the reason for there being no relationship between disease duration and urinary symptoms may be that each patient has a different age at onset (24) .
The severity of disease was assessed using H & Y staging and UPDRS scales. Our findings show that as disease stage and progression increase, the severity and frequency of urologic complaints increase. Disease progression is related more to OAB symptoms like urgency and leaking. A study using urodynamic methods reported that urinary complaints increased with progression of PD, in accordance with the results of our study (16) . Additionally, we identified a positive correlation between UPDRS cognitive and UPDRS daily life scores with irritative complaints (P = 0.004). These results are in accordance with the results of studies by many researchers like Araki and Kuno and Sammour et al. (16, 22) . The researchers reported that severity of urinary complaints increased with disease progression. It was also reported that UPDRS score is associated with erection and lubrication (25) .
Comparing the PD and control groups, urinary complaints were identified significantly more frequently in the PD patient group. The most frequently encountered urinary complaints in the PD patient group were OAB complaints like urgency, frequent urination, and leaking (P < 0.001). After irritative symptoms, the most frequently observed complaints in the PD group were voiding complaints and this rate was 59%, while in the control group this rate was 2.5% (P < 0.001). While the incidence of urological complaints in the PD group was 69.2%, this rate was 7.5% in the control group and these results are in accordance with rates reported in the literature (27%-75%) (13, 15) . The reason for such a broad interval of incidence rates in the literature may be due to patient selection criteria in urology and neurology clinics. Due to difficulty in understanding the questionnaire form, and due to the chronic nature of PD, patients are in close contact with doctors and may have had help from doctors in filling in the form (15, 26) . The IPSS total score and QoL in the PD group were negatively affected compared to the control group. These patients felt they required more treatment to resolve their urologic complaints (P < 0.001). Many studies comply with our results, reporting that urological complaints disrupt the QoL of patients (16, 27) . There was no difference identified between the groups in terms of nocturia (nighttime urination frequency > 1) (P = 0.450).
The reason for increased urological complaints in PD patients has been broadly examined in the literature and studies have reported the role of the dopaminergic system in neurogenic control of the bladder. Symptoms such as urgency, frequent urination, and nocturia, suggesting an OAB due to reduction in dopaminergic functions of the nigrostriatal area, are more commonly encountered in PD (28) . Additionally, studies have reported that the severity of urinary dysfunction in PD is related to the scale of dopamine degeneration, stage of disease, and neurological deficit (29) . A study by Winge et al. identified a correlation between urological complaints and reduction in total counts of dopaminergic neurons and caudate degeneration (30) . The results of the study reported that reduced cortical stimulation from the basal ganglions is a significant cause of urinary symptoms in PD disease. The same study found the dopaminergic medications used for treatment had no effect on resolving or reducing urological complaints.
The limitations of our study are linked to the low number of patients. Another limitation is that advanced assessments such as uroflowmetry, urodynamics, and cystoscopy were not performed for detailed evaluation of patient. Another deficient point of the study is that for patients requiring treatment results after treatment are not known.
In conclusion, in our study, urological complaints were observed more frequently in PD patients compared to the control group. The most commonly observed symptoms were irritative urination symptoms such as urgency and leaking, immediately followed by voiding symptoms. An interesting point of the study is that no difference was found between women and men, though voiding complaints are expected to be more common in men due to prostate disease. The majority of PD patients believe that urological complaints are a result of the neurological disease and think they must live with it and do not share their complaints with doctors. As a result, PD patients should be routinely questioned about urological symptoms and necessary precautions should be taken. This is important both to improve the QoL of patients and to prevent serious problems that may develop in the future.
